Shield Therapeutics PLC Directorate Change (2986C)
June 18 2021 - 2:00AM
UK Regulatory
TIDMSTX
RNS Number : 2986C
Shield Therapeutics PLC
18 June 2021
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Directorate Change
London, UK, 18 June 2021: Shield Therapeutics plc (LSE: STX), a
commercial stage, pharmaceutical company with a focus on addressing
iron deficiency with its lead product Feraccru(R)/Accrufer(R)
(ferric maltol), announces that further to the announcement issued
on 28 May 2021, Greg Madison will join the Board with immediate
effect and is fulfilling the role of the Group's Chief Executive
Officer.
Shield also discloses the following information in accordance
with Schedule 2(g) of the AIM Rules for Companies.
Full name: Gregory Paul Madison
Age: 53 years
Current directorships/partnerships:
-- American Kidney Fund, Board of Trustees
Previous directorships/partnerships held in the past 5
years:
-- Melt Pharmaceuticals, Inc.
-- Keryx Biopharmaceuticals, Inc.
-- Keryx Biopharma UK Ltd.
Mr Madison currently does not hold any ordinary shares in
Shield.
There are no other disclosures required in connection with the
appointment of Mr Madison under Schedule Two(g) of the Aim Rules
for Companies.
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Greg Madison, CEO +44 (0) 191 511 8500
Lucy Huntington-Bailey
Nominated Adviser and Joint
Broker
Peel Hunt LLP
James Steel/Christopher Golden +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/Alice Lane/George
Dollemore +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780 or shield@walbrookpr.com
Paul McManus/Lianne Cawthorne
About Shield Therapeutics plc
Shield is a commercial stage, pharmaceutical company with a
focus on addressing iron deficiency with its lead product Feraccru
(R) /Accrufer (R) (ferric maltol), a novel, stable, non-salt based
oral therapy for adults with iron deficiency with or without
anaemia.
Shield's lead product, Feraccru(R)/Accrufer(R), has been
approved for use in the United States, European Union, UK and
Switzerland and has exclusive IP rights until the mid-2030s. The
Group plans to launch Accrufer(R) in the US during 2021 through a
highly experienced sales and marketing team. Feraccru(R) is already
being commercialised in the UK and European Union by Norgine B.V.,
who also have the marketing rights in Australia and New Zealand.
Shield also has an exclusive licence agreement with Beijing
Aosaikang Pharmaceutical Co., Ltd., for the development and
commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong,
Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com.
Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAMZGMVKNLGMZM
(END) Dow Jones Newswires
June 18, 2021 02:00 ET (06:00 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024